Drug intelligence / Profile preview

dicyclomine hydrochloride + simethicone

Development stage
Phase 4
Lead developer
Crest Lifesciences
Modality
Small Molecules
Administration
Oral
01

Overview

Dicyclomine hydrochloride + simethicone is a fixed-dose combination pharmaceutical product used for the symptomatic relief of gastrointestinal disorders involving smooth muscle spasms and excess gas. Dicyclomine hydrochloride is an antispasmodic and anticholinergic agent that works by antagonizing muscarinic acetylcholine receptors in the gastrointestinal tract, thereby reducing intestinal motility and cramping. Simethicone is an anti-foaming agent that acts as a surfactant to decrease the surface tension of gas bubbles, allowing them to coalesce and be expelled more easily. This combination is commonly prescribed for irritable bowel syndrome (IBS), functional bowel disorders, abdominal pain, and infantile colic. It is manufactured by Crest Lifesciences in various oral formulations, including tablets and suspensions.

Other names
dicyclomine + simethiconedicycloverine hydrochloride + simethiconedicycloverine + simethicone
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)

Beyond the preview

Go deeper on dicyclomine hydrochloride + simethicone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dicyclomine hydrochloride + simethicone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call